Compare Dyne Therapeutics Inc. Common Stock (DYN) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs FuelCell Energy Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while FuelCell Energy Inc trades at $13.96 (market cap $1.24B). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.3× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and FuelCell Energy Inc for 48 Days on average.
| DYN | FCEL | |
|---|---|---|
Market Cap | $2.86B | $1.24B |
Volume | 3,341,579 | 7,483,477 |
Sector | Health | Industrials |
52-Week High | $26.78 | $36.01 |
52-Week Low | $14.60 | $6.00 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $2.18B | $818.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
FuelCell Energy (FCEL) trades at $14.16, down 13.5% over 24 hours, reflecting negative momentum amid ongoing operational losses. The stock exhibits a bearish technical signal, with key support at $14. Recent financials show revenue of $158.16M in 2025 but a net loss of $187.90M, with negative gross and net income margins. Analyst consensus is split evenly between Buy and Hold, with a $21.57 price target. Multiple law firms have announced securities class actions related to disclosures from June to September 2026, adding legal overhangs.
FCEL's outlook remains challenged by persistent unprofitability and cash burn, though analyst targets suggest potential upside from current levels. Key risks include the class action lawsuits, execution on scaling power agreements, and the company's ability to achieve positive cash flow. The stock presents a high-risk opportunity contingent on operational turnaround and resolution of legal issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
